Identification

Name
Naftifine
Accession Number
DB00735  (APRD01131)
Type
Small Molecule
Groups
Approved
Description

Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.

Structure
Thumb
Synonyms
  • Naftifin
  • Naftifina
  • Naftifine
  • Naftifinum
External IDs
AW 105 843 / SN 105843
Product Ingredients
IngredientUNIICASInChI Key
Naftifine Hydrochloride25UR9N904165473-14-5OLUNPKFOFGZHRT-YGCVIUNWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naftifine HydrochlorideCream1 mg/gTopicalRenaissance Pharma, Inc.2015-06-01Not applicableUs
Naftifine HydrochlorideCream20 mg/gTopicalRenaissance Pharma, Inc.2016-02-01Not applicableUs
NaftinCream10 mg/gTopicalMerz Pharmaceuticals1998-06-01Not applicableUs
NaftinGel10 mg/gTopicalPhysicians Total Care, Inc.2005-12-29Not applicableUs
NaftinCream10 mg/2gTopicalMerz Pharmaceuticals2012-03-01Not applicableUs
NaftinGel10 mg/gTopicalMerz Pharmaceuticals1990-10-01Not applicableUs
NaftinCream10 mg/gTopicalPhysicians Total Care, Inc.2010-06-17Not applicableUs
NaftinGel2 g/100gTopicalMerz Pharmaceuticals2013-09-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naftifine HydrochlorideCream10 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2016-09-08Not applicableUs
Naftifine HydrochlorideCream20 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2016-01-06Not applicableUs
Naftifine HydrochlorideCream20 mg/gTopicalImpax Generics2017-05-10Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naftin Crm 1%Cream1 %TopicalAllergan Herbert Skin Care Division Of Allergan Inc.1993-12-312011-08-04Canada
Naftin Gel 1%Gel1 %TopicalAllergan Herbert Skin Care Division Of Allergan Inc.1993-12-312011-08-04Canada
International/Other Brands
A Mei (Shou Chan) / Ancent (Yuan Chou) / Exoderil (Sandoz) / Micosona (Bayer) / Naftifina (Antibiotice) / Naftin / Suadian (Sandoz)
Categories
UNII
4FB1TON47A
CAS number
65472-88-0
Weight
Average: 287.3981
Monoisotopic: 287.167399677
Chemical Formula
C21H21N
InChI Key
OZGNYLLQHRPOBR-DHZHZOJOSA-N
InChI
InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+
IUPAC Name
methyl(naphthalen-1-ylmethyl)(3-phenylprop-2-en-1-yl)amine
SMILES
CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12

Pharmacology

Indication

For the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.

Structured Indications
Pharmacodynamics

Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative. The following in vitro data are available, but their clinical significance is unknown. Naftifine has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, and Microsporum canis, Microsporum audouini, and Microsporum gypseum; and fungistatic activity against Candida species including Candida albicans. However it is only used to treat the organisms listed in the indications.

Mechanism of action

Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.

TargetActionsOrganism
ASqualene monooxygenase
inhibitor
Human
Absorption

Following single topical applications of 3H-labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.

Half life

Approximately 2 to 3 days following topical administration.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Yeast and other fungi
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Naftifine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Naftifine is combined with 5-androstenedione.Experimental, Illicit
AbciximabNaftifine may increase the anticoagulant activities of Abciximab.Approved
AcebutololNaftifine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Naftifine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Naftifine is combined with Acemetacin.Approved
AcenocoumarolNaftifine may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinNaftifine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Naftifine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Naftifine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Naftifine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Alendronic acid.Approved
AliskirenNaftifine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Alminoprofen.Experimental
AlprenololNaftifine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Naftifine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Amcinonide.Approved
AmikacinNaftifine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNaftifine may decrease the antihypertensive activities of Amiloride.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Naftifine.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Amrinone.Approved
AmrubicinNaftifine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNaftifine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Naftifine is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Naftifine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Naftifine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Naftifine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Naftifine is combined with Anisodamine.Investigational
annamycinNaftifine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Naftifine is combined with Antipyrine.Approved
Antithrombin III humanNaftifine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanNaftifine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Naftifine is combined with Apocynin.Investigational
ApramycinNaftifine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Naftifine is combined with Apremilast.Approved, Investigational
ArbekacinNaftifine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNaftifine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNaftifine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNaftifine may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Naftifine is combined with Atamestane.Investigational
AtenololNaftifine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Naftifine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Naftifine is combined with Azimilide.Investigational
BalsalazideNaftifine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Barnidipine.Approved
BecaplerminNaftifine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Naftifine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNaftifine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNaftifine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Naftifine.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Naftifine is combined with Bencyclane.Experimental
BendazacThe risk or severity of adverse effects can be increased when Naftifine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naftifine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Benidipine.Approved, Investigational
BenorilateThe risk or severity of adverse effects can be increased when Naftifine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Naftifine is combined with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Naftifine is combined with Bepridil.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Naftifine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Betamethasone.Approved, Vet Approved
BetaxololNaftifine may decrease the antihypertensive activities of Betaxolol.Approved
BevantololNaftifine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Naftifine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Naftifine.Approved, Investigational
BisoprololNaftifine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNaftifine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNaftifine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Naftifine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bucillamine.Investigational
BucindololNaftifine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Naftifine is combined with Bufexamac.Experimental
BufuralolNaftifine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Bumadizone.Experimental
BumetanideNaftifine may decrease the diuretic activities of Bumetanide.Approved
BupranololNaftifine may decrease the antihypertensive activities of Bupranolol.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Naftifine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Naftifine.Approved, Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Naftifine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Naftifine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Naftifine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Naftifine.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Naftifine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Naftifine.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Naftifine is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Naftifine is combined with Caroverine.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNaftifine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNaftifine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Naftifine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Naftifine.Approved, Investigational
CeliprololNaftifine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNaftifine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Naftifine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naftifine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naftifine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Naftifine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naftifine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cinnarizine.Approved, Investigational
CinoxacinNaftifine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Naftifine.Approved, Investigational, Withdrawn
Citric AcidNaftifine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clevidipine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Naftifine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Naftifine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Naftifine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Naftifine is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Naftifine.Vet Approved
CloranololNaftifine may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Naftifine.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Naftifine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Naftifine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Naftifine is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Naftifine is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naftifine.Experimental
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Naftifine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Naftifine is combined with D-Limonene.Investigational
Dabigatran etexilateNaftifine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNaftifine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNaftifine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNaftifine may increase the anticoagulant activities of Darexaban.Investigational
DarodipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Darodipine.Experimental
DaunorubicinNaftifine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Naftifine is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Naftifine is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Naftifine.Experimental
DesirudinNaftifine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Naftifine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Naftifine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Naftifine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Naftifine.Approved, Investigational
DextranNaftifine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Naftifine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Naftifine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Naftifine may increase the anticoagulant activities of Dextran 75.Approved
DibekacinNaftifine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Naftifine.Approved, Vet Approved
DicoumarolNaftifine may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineDidanosine can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Naftifine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Naftifine is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Naftifine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Naftifine.Approved
DihydrostreptomycinNaftifine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Naftifine is combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Naftifine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Naftifine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Naftifine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Naftifine.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Naftifine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Naftifine is combined with Dotarizine.Investigational
DoxorubicinNaftifine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNaftifine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Naftifine is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Naftifine is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Naftifine is combined with E-6201.Investigational
Edetic AcidNaftifine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNaftifine may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Efonidipine.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Naftifine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Naftifine.Approved
EnoxacinNaftifine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNaftifine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Naftifine.Experimental
EpanololNaftifine may decrease the antihypertensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Eperisone.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Naftifine is combined with Epirizole.Approved
EpirubicinNaftifine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNaftifine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naftifine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naftifine.Approved
EquileninThe risk or severity of adverse effects can be increased when Naftifine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Naftifine is combined with Equilin.Approved
EsmololNaftifine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Naftifine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Naftifine is combined with Estrone sulfate.Approved
Etacrynic acidNaftifine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Naftifine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Naftifine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateNaftifine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Naftifine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Naftifine is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Naftifine is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Naftifine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Naftifine is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Naftifine is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Naftifine is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Naftifine is combined with Fenbufen.Approved
FendilineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fendiline.Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naftifine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Naftifine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Naftifine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Feprazone.Experimental
Ferulic acidNaftifine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Naftifine.Approved, Investigational
FleroxacinNaftifine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Naftifine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Naftifine is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Fludrocortisone.Approved
FluindioneNaftifine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNaftifine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Naftifine is combined with Flunarizine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Naftifine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Naftifine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Naftifine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Naftifine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naftifine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Naftifine.Approved, Nutraceutical, Vet Approved
FondaparinuxNaftifine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNaftifine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Naftifine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Naftifine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Naftifine.Approved
FosphenytoinThe serum concentration of Naftifine can be decreased when it is combined with Fosphenytoin.Approved
FramycetinNaftifine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNaftifine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Naftifine is combined with Gabapentin.Approved, Investigational
GabexateNaftifine may increase the anticoagulant activities of Gabexate.Investigational
GallopamilThe risk or severity of adverse effects can be increased when Naftifine is combined with Gallopamil.Investigational
GarenoxacinNaftifine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNaftifine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Naftifine.Approved, Withdrawn
GemifloxacinNaftifine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNaftifine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNaftifine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANaftifine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Naftifine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNaftifine may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Naftifine is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Naftifine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Naftifine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Naftifine is combined with HE3286.Investigational
HeparinNaftifine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Naftifine is combined with Higenamine.Investigational
HydralazineNaftifine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naftifine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naftifine.Approved, Investigational
Hygromycin BNaftifine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Naftifine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Naftifine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Naftifine is combined with Icatibant.Approved
IdarubicinNaftifine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNaftifine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naftifine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Naftifine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Naftifine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naftifine.Approved
IndenololNaftifine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Naftifine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naftifine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Indoprofen.Withdrawn
INNO-206Naftifine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Naftifine.Approved, Investigational
IsepamicinNaftifine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Naftifine is combined with Isoxicam.Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Naftifine is combined with Istaroxime.Investigational
KanamycinNaftifine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Naftifine.Approved
LabetalolNaftifine may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lamotrigine.Approved, Investigational
LandiololNaftifine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Naftifine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Naftifine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Naftifine is combined with Leflunomide.Approved, Investigational
LepirudinNaftifine may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lercanidipine.Approved, Investigational
LetaxabanNaftifine may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNaftifine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNaftifine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lidoflazine.Experimental
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Naftifine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Naftifine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Naftifine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Naftifine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Naftifine is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Naftifine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Naftifine is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Naftifine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Naftifine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Naftifine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Naftifine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Naftifine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Mefenamic acid.Approved
MelagatranNaftifine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Naftifine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Naftifine is combined with Meloxicam.Approved, Vet Approved
MepindololNaftifine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineNaftifine may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Naftifine is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Naftifine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naftifine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNaftifine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine.Approved
MetoprololNaftifine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNaftifine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe risk or severity of adverse effects can be increased when Naftifine is combined with Mibefradil.Investigational, Withdrawn
MicronomicinNaftifine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Naftifine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Naftifine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Naftifine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naftifine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Naftifine.Approved
NadololNaftifine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNaftifine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNaftifine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftifine is combined with Naftopidil.Investigational
Nalidixic AcidNaftifine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naftifine is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Naftifine is combined with NCX 1022.Investigational
NeamineNaftifine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNaftifine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinNaftifine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNaftifine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Naftifine.Approved
NetilmicinNaftifine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Naftifine is combined with Niflumic Acid.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Naftifine is combined with Nitroaspirin.Investigational
NorfloxacinNaftifine may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Naftifine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Naftifine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Naftifine is combined with Olopatadine.Approved
OlsalazineNaftifine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Naftifine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Naftifine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Naftifine is combined with Orgotein.Vet Approved
OtamixabanNaftifine may increase the anticoagulant activities of Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Naftifine is combined with Otilonium.Experimental, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxaprozin.Approved
Oxolinic acidNaftifine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNaftifine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Naftifine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Naftifine is combined with Parecoxib.Approved
ParomomycinNaftifine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Naftifine is combined with Parthenolide.Investigational
PazufloxacinNaftifine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNaftifine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNaftifine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNaftifine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateNaftifine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Naftifine is combined with Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Naftifine.Approved
PhenindioneNaftifine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNaftifine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Naftifine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naftifine.Approved, Investigational
PimozideNaftifine may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Naftifine is combined with Pinaverium.Approved
PindololNaftifine may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidNaftifine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNaftifine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNaftifine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Pirfenidone.Approved, Investigational
Piromidic acidNaftifine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naftifine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Pirprofen.Experimental
Platelet Activating FactorNaftifine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNaftifine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNaftifine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Naftifine.Approved
PractololNaftifine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Naftifine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Naftifine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Naftifine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Naftifine is combined with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Pregnenolone.Experimental, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prenylamine.Withdrawn
ProbenecidThe serum concentration of Naftifine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Naftifine.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Naftifine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Naftifine is combined with Propacetamol.Approved, Investigational
PropranololNaftifine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Naftifine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Naftifine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Naftifine.Vet Approved
Protein CNaftifine may increase the anticoagulant activities of Protein C.Approved
Protein S humanNaftifine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNaftifine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNaftifine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Naftifine is combined with PTC299.Investigational
PuromycinNaftifine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Naftifine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naftifine.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Naftifine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Naftifine.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Naftifine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naftifine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinNaftifine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNaftifine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Naftifine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Naftifine.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Naftifine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Naftifine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Naftifine is combined with Risedronate.Approved, Investigational
RivaroxabanNaftifine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Naftifine.Investigational, Withdrawn
RosoxacinNaftifine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinNaftifine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNaftifine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Naftifine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Naftifine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Naftifine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naftifine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Naftifine.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Naftifine is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Naftifine is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Naftifine is combined with Serrapeptase.Investigational
SisomicinNaftifine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNaftifine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Naftifine.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Naftifine.Approved
SotalolNaftifine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNaftifine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNaftifine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinNaftifine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Naftifine.Approved
SpironolactoneNaftifine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Naftifine is combined with SRT501.Investigational
StreptomycinNaftifine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNaftifine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SucralfateSucralfate can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Naftifine is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Naftifine.Approved
SulodexideNaftifine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Naftifine.Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Naftifine.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Naftifine is combined with Suxibuzone.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Naftifine.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Naftifine.Approved
TalinololNaftifine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Naftifine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Naftifine is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Naftifine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Naftifine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Naftifine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naftifine.Approved, Investigational
TemafloxacinNaftifine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Naftifine.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Naftifine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Naftifine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naftifine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Naftifine is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Naftifine is combined with Teriflunomide.Approved
TerodilineThe risk or severity of adverse effects can be increased when Naftifine is combined with Terodiline.Experimental
TertatololNaftifine may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tetrahydropalmatine.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNaftifine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Naftifine is combined with Tixocortol.Approved
TobramycinNaftifine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Naftifine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naftifine.Approved
TorasemideNaftifine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Naftifine.Approved
TranilastThe risk or severity of adverse effects can be increased when Naftifine is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naftifine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naftifine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Naftifine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNaftifine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Naftifine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naftifine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Naftifine is combined with Triptolide.Investigational
TrovafloxacinNaftifine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNaftifine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Naftifine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Naftifine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Naftifine.Investigational, Withdrawn
ValrubicinNaftifine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Naftifine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Naftifine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Naftifine is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Naftifine is combined with Vinpocetine.Investigational
WarfarinNaftifine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNaftifine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Naftifine is combined with Xylometazoline.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Naftifine is combined with Zaltoprofen.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Naftifine is combined with Ziconotide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Naftifine is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Naftifine.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Naftifine is combined with Zoledronic acid.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Naftifine.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Naftifine is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinNaftifine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNaftifine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference
US4282251
General References
Not Available
External Links
KEGG Compound
C08071
PubChem Compound
73342
PubChem Substance
46504777
ChemSpider
43344
BindingDB
50170647
ChEBI
7451
ChEMBL
CHEMBL626
Therapeutic Targets Database
DAP000752
PharmGKB
PA164748617
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Naftifine
ATC Codes
D01AE22 — Naftifine
MSDS
Download (14.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentTinea Pedis3
3CompletedTreatmentTinea Cruris1
3CompletedTreatmentTinea Pedis4
4CompletedTreatmentTinea Corporis2
4CompletedTreatmentTinea Cruris / Tinea Pedis1

Pharmacoeconomics

Manufacturers
  • Merz pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
CreamTopical1 mg/g
CreamTopical20 mg/g
CreamTopical10 mg/2g
CreamTopical10 mg/g
GelTopical10 mg/g
GelTopical2 g/100g
CreamTopical1 %
GelTopical1 %
Prices
Unit descriptionCostUnit
Naftin 1% Gel 90 gm Tube290.08USD tube
Naftin 1% Cream 90 gm Tube248.26USD tube
Naftin 1% Gel 60 gm Tube208.5USD tube
Naftin 1% Cream 60 gm Tube183.77USD tube
Naftin 1% Gel 40 gm Tube147.0USD tube
Naftin 1% Cream 30 gm Tube101.62USD tube
Naftin pump 1% cream3.2USD g
Naftin 1% cream2.45USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9161914No2013-01-312033-01-31Us
US8778365No2013-01-312033-01-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP5.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000229 mg/mLALOGPS
logP4.96ALOGPS
logP5.24ChemAxon
logS-6.1ALOGPS
pKa (Strongest Basic)9.08ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity95.98 m3·mol-1ChemAxon
Polarizability34.05 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9713
Caco-2 permeable+0.812
P-glycoprotein substrateSubstrate0.525
P-glycoprotein inhibitor INon-inhibitor0.8649
P-glycoprotein inhibitor IIInhibitor0.6605
Renal organic cation transporterInhibitor0.5834
CYP450 2C9 substrateNon-substrate0.7661
CYP450 2D6 substrateNon-substrate0.829
CYP450 3A4 substrateNon-substrate0.5646
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorNon-inhibitor0.876
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.5561
CarcinogenicityNon-carcinogens0.6525
BiodegradationNot ready biodegradable0.9926
Rat acute toxicity2.5407 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6159
hERG inhibition (predictor II)Non-inhibitor0.6593
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014r-0940000000-736e1306e0a1b21a69e5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-1a47528b60d38f7230ea
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-db364fa78b21edf4eb3a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-43af6cd3170ea07037e0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-0900000000-2a982f932855fa74205f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-1900000000-6aded55bd308a6ddc1e8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-4900000000-382482d4ffa5075b4d29
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-8900000000-ad11e6913754f48ce01d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9400000000-52e2c99bae16686c15b3

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Styrenes / Aralkylamines / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Naphthalene / Styrene / Aralkylamine / Monocyclic benzene moiety / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Squalene monooxygenase activity
Specific Function
Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway.
Gene Name
SQLE
Uniprot ID
Q14534
Uniprot Name
Squalene monooxygenase
Molecular Weight
63922.505 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Favre B, Ryder NS: Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7. [PubMed:8834895]
  3. Vanden Bossche H, Marichal P: Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. [PubMed:1951574]
  4. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA: Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003 Jan;47(1):82-6. [PubMed:12499173]
  5. Ryder NS, Dupont MC: Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes. Biochem J. 1985 Sep 15;230(3):765-70. [PubMed:3877503]
  6. Ryder NS, Frank I: Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol. 1992;30(6):451-60. [PubMed:1287164]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:42